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OBJECTIVES We sought to investigate the effect of angiotensin-converting enzyme (ACE) inhibition ,9 h
after myocardial infarction (MI) on left ventricular (LV) dilation in patients receiving
thrombolysis.
BACKGROUND The ACE inhibitors reduce mortality after MI. Attenuation of LV dilation has been
suggested as an important mechanism.
METHODS The data of 845 patients with three-month echocardiographic follow-up after MI were
combined from three randomized, double-blind, placebo-controlled studies. The criteria for
these studies included: 1) thrombolytic therapy; 2) ACE inhibition within 6 to 9 h; and 3)
evaluation of LV dilation as the primary objective.
RESULTS The ACE inhibitor was started 3.2 6 1.7 h after the patients’ first (mainly, 85%) anterior MI.
After three months, LV dilation was not significantly attenuated by very early treatment with
an ACE inhibitor. The diastolic volume index was attenuated by 0.5 ml/m2 (95% confidence
interval [CI] 21.5 to 2.5, p 5 0.61), and the systolic volume index by 0.5 ml/m2 (95% CI
21.0 to 1.9, p 5 0.50). Subgroup analysis demonstrated that LV dilation was significantly
attenuated by ACE inhibitor treatment for patients in whom reperfusion failed. In contrast,
LV dilation was almost unaffected by ACE inhibitor treatment in successfully reperfused
patients.
CONCLUSIONS We could not demonstrate attenuation of LV dilation in patients receiving thrombolysis by
ACE inhibitor treatment within 6 to 9 h after MI. We speculate that very early treatment
with an ACE inhibitor has a beneficial effect on LV remodeling only in patients in whom
reperfusion failed. Other mechanisms may be responsible for the beneficial effects of ACE
inhibitors in successfully reperfused patients after MI. (J Am Coll Cardiol 2000;36:2047–53)
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The important role of angiotensin-converting enzyme
(ACE) inhibitors in reducing mortality after myocardial
infarction (MI) has been well established (1). The optimal
timing of treatment with an ACE inhibitor after MI, as well
as the exact mechanisms leading to the beneficial effects of
ACE inhibitors, have not been completely resolved. Timing
of ACE inhibitors after MI in large mortality trails was
either late (.3 days) or early (,24 to 36 h) (1). The
beneficial effects of very early (,6 h) ACE inhibitor
treatment on cardiac death have only been demonstrated in
one recent angiographic study (2). Because mortality is
directly related to the extent of left ventricular (LV) dilation
(3), an important suggested mechanism by which ACE
inhibitors produce their beneficial effects is attenuation of
LV dilation (4). Previously, we performed a study in 298
patients receiving thrombolysis after their first anterior wall
MI, to address the effect of very early treatment with an
See page 2054
ACE inhibitor on LV dilation (5,6). In this study, only a
modest beneficial effect of ACE inhibitor treatment on LV
dilation was demonstrated during one year of follow-up,
and it was calculated that at least 700 patients would have
been needed to conclude a true effect of ACE inhibitors on
ventricular dilation. Therefore, in the present study, we
combined the data of 845 patients from three similar
randomized, double-blind, placebo-controlled, echocardio-
graphic studies who received thrombolysis after MI. The
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aim of the present study was to assess the effect of treatment
with an ACE inhibitor within 6 to 9 h on LV dilation in
patients receiving thrombolysis, mainly after their first
anterior MI.
METHODS
Study design. We combined the data of 845 patients
receiving thrombolysis from three multicenter, randomized,
double-blind, placebo-controlled, echocardiographic stud-
ies, which initiated ACE inhibitor treatment 3.2 6 1.70 h
after the onset of mainly (85%) their first anterior MI. This
resulted in a data base containing the data of all studies
performed in this setting, with the primary objective being
assessment of the effect of very early treatment with an ACE
inhibitor on LV dilation, with at least one-month echocar-
diographic follow-up. The three studies included in this
meta-analysis were the Captopril And Thrombolysis Study
(CATS, n 5 298, April 1990 to December 1992), the
Fosinopril in Acute Myocardial Infarction Study (FAMIS,
n 5 285, January 1992 to June 1993) and the CAPtopril
plus Tissue plasminogen activator following acute myocar-
dial INfarction study (CAPTIN, n 5 262, September 1990
to July 1992). Only CATS (5,6) and FAMIS (7,8) have
been published as full reports. Of the 845 patients included
in this meta-analysis, 421 were randomized to placebo and
424 to an ACE inhibitor; 711 patients (84%) had at least
one echocardiographic assessment. Double-blind placebo or
ACE inhibitor treatment was initiated either immediately
on completion of thrombolytic therapy (CATS and
CAPTIN) or within 3 h after thrombolysis (FAMIS). In
CAPTIN, 2 to 4 mg captopril was initially administered
intravenously within 6 h after MI, followed by the first oral
dose of 6.25 mg 2 h after thrombolytic therapy. In CATS,
administration of 6.25 mg captopril orally was started
within 6 h after MI. If tolerated, both CATS and CAPTIN
gradually adjusted the dose upward to 25 mg. The initial
oral dose of fosinopril in FAMIS was administrated within
9 h of MI and was 5 mg for the first two days, and if
tolerated, titrated upward to 20 mg. Treatment with an
ACE inhibitor continued until the end of the study (one
year for CATS and three months for FAMIS and
CAPTIN).
Patients. The three studies were very similar in terms of
patient selection criteria. Patients were considered eligible if
MI was diagnosed on the basis of the presence of symptoms
and at least 2-mm ST segment elevation in two or more
precordial leads (V1 to V6). In addition, patients had to be
eligible for thrombolytic therapy immediately after admis-
sion to the coronary care unit (continuous intravenous
infusion of streptokinase [1,000,000 IU during 30 min] in
CATS and FAMIS or recombinant tissue-type plasmino-
gen activator [60 mg in the first hour, 20 mg in the second
and third hours] in CAPTIN). Thrombolytic therapy had
to be administered within 6 h (CATS and CAPTIN) or
within 8 h (FAMIS) after the onset of MI symptoms.
During double-blind therapy, all patients received the usual
recommended therapy, including beta-blockers and aspirin.
Echocardiographic measurements. In CATS, LV volume
was measured by serial two-dimensional echocardiograms at
1, 3 and 10 days and 3 and 12 months; in FAMIS, within
2 days, at hospital discharge (15 days) and at 3 months; and
in CAPTIN, at 3 days and 1 and 3 months after the onset
of symptoms. In the three studies, the echocardiographic
methods were similar, as reported previously (5,7). For each
of the three studies, the echocardiograms were centrally
evaluated in a single echocardiographic core laboratory. The
echocardiographic analysis was performed without knowl-
edge of the study medication and echocardiogram sequence.
Reperfusion status. Reperfusion was assessed clinically, as
relief of chest pain, rapid reversal of ischemic electrocardio-
graphic changes, rapid peak of creatine kinase (within 16 h
after onset of symptoms) and typical transient arrhythmias.
At least three of these four findings had to be present to
conclude that reperfusion was successful after thrombolysis
(7).
Statistical analysis. Analysis was performed on an
intention-to-treat basis. Continuous baseline characteristics
are expressed as the mean value 6 SD if normally distrib-
uted, and the median value (interquartile range) if distrib-
uted skewed. The differences were tested by one-way
analysis of variance or by the Kruskal-Wallis test, when
appropriate. Categorical variables were described by fre-
quencies and percentages, and the chi-square test was used.
A random-effects model for longitudinal data (SAS,
version 6.12, PROC MIXED, Cary, North Carolina) (9)
was used to test the attenuation of LV systolic and diastolic
volume indexes by ACE inhibition. Logarithmic-
transformed LV volume indexes were analyzed. Mean
values and standard errors were back-transformed. The
effects of ACE inhibitors on LV dilation were corrected for
significant baseline characteristics and the differences be-
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tween trials. All p values were two-sided; p , 0.05 was
considered statistically significant.
RESULTS
Patient characteristics. Although the patient selection
criteria for the three studies were similar, there were some
differences in baseline characteristics (Table 1). The
CAPTIN study included patients with larger infarctions,
as compared with FAMIS and CATS. In CATS, there
were fewer patients with hypertension and preexisting
ischemic heart disease, and the mean arterial pressure was
lower. Despite these differences, owing to the random
assignment to the two treatment groups (placebo and ACE
inhibitor), the baseline characteristics of the groups were
comparable (Table 2). The overall successful reperfusion
rate was 74%. During the first 10 days after MI, 4.9% of
patients, and during the first three months, 7.7% of patients
initially randomized to placebo, crossed over to active
treatment.
Left ventricular dilation. Except for the baseline assess-
ment in the CAPTIN study, for each of the three studies,
the mean LV volume indexes were comparable between the
two groups (Table 3). When combining the studies, the
patients receiving placebo and those treated with an ACE
inhibitor showed very comparable LV diastolic and systolic
dilation (Fig. 1). Treatment with an ACE inhibitor did not
significantly attenuate the LV diastolic volume index at
three months by 0.5 ml/m2 (95% CI 21.5 to 2.5) and also
did not significantly attenuate the LV systolic volume index
by 0.5 ml/m2 (95% CI 21.0 to 1.9). However, at three
months after MI, LV systolic and diastolic volume indexes
were significantly increased as compared with baseline, for
both the ACE inhibitor and placebo groups. The diastolic
volume index increased for the ACE inhibitor group by
3.9 ml/m2 (95% CI 2.5 to 5.3), and for the placebo group by
4.3 ml/m2 (95% CI 3.0 to 5.6). The systolic volume index
increased for the ACE inhibitor group by 1.4 ml/m2 (95%
CI 0.4 to 2.4), and for the placebo group by 1.9 ml/m2 (95%
CI 0.9 to 2.8). The lack of an effect of ACE inhibitor
therapy on LV diastolic and systolic dilation was consis-
tently found among the subgroups (Fig. 2). However,
treatment with an ACE inhibitor in the subgroup of
patients in whom reperfusion failed resulted in significant
attenuation of both LV diastolic and systolic dilation after
thrombolytic therapy, as compared with placebo (Fig. 3). In
contrast, LV dilation was almost unaffected by treatment
with an ACE inhibitor in successfully reperfused patients.
For patients in whom reperfusion failed, ACE inhibitor
treatment resulted in attenuation of the LV diastolic volume
index by 4.9 ml/m2 (95% CI 0.7 to 8.8), as well as
attenuation of the LV systolic volume index by 4.0 ml/m2
(95% CI 1.2 to 6.4), both at three months. Furthermore,
both LV systolic and diastolic dilations were significantly
more pronounced for patients in whom reperfusion failed, as
compared with successfully reperfused patients (Fig. 4). The
additional increase in the LV diastolic volume index of
patients in whom reperfusion failed over that of successfully
Table 1. Baseline Characteristics of the Patients of Studies Included in This Meta-Analysis
Characteristics
CATS
(n 5 298)
FAMIS
(n 5 285)
CAPTIN
(n 5 262)
Age (yrs) 59 6 10 60 6 10 59 6 10
Males 224 (75%) 235 (85%) 209 (80%)
Mean arterial pressure (mm Hg)* 93 6 14 102 6 15 99 6 15
Heart rate (beats/min)† 82 6 15 78 6 15 80 6 15
Body surface area (m2)* 1.90 6 0.16 1.84 6 0.17 1.94 6 0.22
Killip class I 224 (75%) 227 (80%) 189 (72%)
Killip class II 72 (24%) 57 (20%) 71 (27%)
Clinical history
Ischemic heart disease* 26 (9%) 65 (23%) 42 (16%)
Hypertension* 65 (22%) 104 (36%) 97 (37%)
Diabetes mellitus* 28 (9%) 42 (15%) 52 (20%)
Current smoker† 186 (63%) 148 (52%) 149 (57%)
Medication history
Beta blockers* 57 (19%) 24 (8%) 38 (15%)
Calcium antagonists† 42 (14%) 50 (18%) 22 (8%)
Diuretics† 35 (12%) 12 (4%) 18 (7%)
Nitrates 30 (10%) 24 (8%) 37 (14%)
Echocardiographic measures
Systolic volume index (ml/m2)† 24 (18–32) 27 (20–34) 27 (20–33)
Diastolic volume index (ml/m2)† 55 (47–62) 55 (46–64) 51 (45–61)
Ejection fraction (%)* 56 (47–62) 50 (44–57) 49 (42–55)
Peak creatine kinase (IU/1,000)* 1.36 (0.7–2.50) 1.85 (0.9–3.1) 2.28 (0.9–3.8)
Reperfusion 188 (73%) 206 (73%) 199 (76%)
*Significantly different (p , 0.001). †Significantly different (0.01 , p , 0.05). Data are presented as the mean value 6 SD,
number (%) of patients or median value (interquartile range).
CAPTIN 5 CAPtopril plus Tissue plasminogen activator following acute myocardial INfarction study; CATS 5 Captopril
And Thrombolysis Study; FAMIS 5 Fosinopril in Acute Myocardial Infarction Study.
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reperfused patients was 4.0 ml/m2 (95% CI 0.7 to 5.3), and
the additional increase in the LV systolic volume index was
3.1 ml/m2 (95% CI 0.7 to 5.3), both at three months.
DISCUSSION
This meta-analysis of 845 patients receiving thrombolysis in
three prospective, randomized, double-blind, placebo-
controlled studies shows that LV dilation at three months is
not significantly attenuated by treatment with an ACE
inhibitor within 6 to 9 h after the patients’ first (mainly)
anterior MI (Fig. 1). Subgroup analysis, however, suggests a
beneficial effect of ACE inhibition on LV dilation for
patients in whom thrombolytic therapy failed to establish
reperfusion (Fig. 3). In contrast, subgroup analysis showed
no effect of ACE inhibition on LV dilation in reperfused
patients. In accordance with previous studies (10,11), sub-
group analysis in the present study showed significant
prevention of LV dilation after successful reperfusion after
MI (Fig. 4). There are three major differences between the
present study and most other echocardiographic studies.
First, in the present study, all patients were treated with
thrombolytic therapy at arrival in the coronary care unit.
Second, patients were not selected on the basis of ventricular
dysfunction. Third, ACE inhibitor treatment was started
very early (i.e., within 6 to 9 h) after MI. These differences
may explain the result of no significant attenuation of LV
dilation by treatment with an ACE inhibitor as compared
with placebo.
Thrombolytic therapy. The first possible reason for our
finding of no significant attenuation of LV dilation may be
the administration of thrombolytic therapy. The first evi-
dence of attenuation of LV dilation produced by ACE
inhibition as compared with placebo was obtained from
experimental studies of occluded arteries (12). Some small
echocardiographic studies showed large effects of ACE
inhibition on LV dilation, but they were conducted in
Figure 1. The effect of ACE inhibitor treatment within 6 to 9 h on LV
dilation in patients receiving thrombolysis (n 5 845) after MI. Data are
presented as the mean value 6 SEM.
Table 2. Baseline Characteristics of the Patients Randomly
Allocated to Placebo and Angiotensin-Converting Enzyme
Inhibitor Treatment
Characteristics
Placebo
(n 5 421)
Ace Inhibitor
(n 5 424)
Age (years) 60 6 10 59 6 10
Males 343 (81%) 325 (77%)
Mean arterial pressure (mm Hg) 98 6 15 98 6 15
Heart rate (beats/min) 80 6 14 80 6 15
Body surface area (m2) 1.90 6 0.18 1.89 6 0.19
Killip class I 317 (75%) 323 (76%)
Killip class II 103 (25%) 97 (24%)
Clinical history
Ischemic heart disease 55 (13%) 78 (18%)
Hypertension 114 (27%) 152 (36%)
Diabetes mellitus 53 (13%) 69 (16%)
Current smoker 226 (54%) 257 (61%)
Medication history
Beta-blockers 54 (13%) 65 (15%)
Calcium antagonists 57 (14%) 57 (13%)
Diuretics 29 (7%) 36 (8%)
Nitrates 41 (10%) 50 (12%)
Echocardiographic measures
Systolic volume index (ml/m2) 26 (20–32) 26 (20–34)
Diastolic volume index (ml/m2) 54 (46–61) 54 (46–63)
Ejection fraction (%) 54 (46–61) 54 (46–63)
Peak creatine kinase (IU/1,000) 1.80 (0.8–3.1) 1.70 (0.9–3.1)
Reperfusion 312 (77%) 281 (70%)
Data are presented as the mean value 6 SD, number (%) of patients or median value
(interquartile range).
ACE 5 angiotensin-converting enzyme.
Table 3. Mean Ventricular Volume Indexes for Each of the Studies Separately (CATS, FAMIS and CAPTIN)
Baseline Discharge 3-Month Follow-Up
Placebo
ACE
Inhibitor Placebo
ACE
Inhibitor Placebo
ACE
Inhibitor
Mean CATS 24.2 6 0.84 23.6 6 0.89 26.7 6 0.97 24.3 6 0.98 26.9 6 1.25 25.3 6 1.25
LVESVI FAMIS 25.6 6 0.93 26.8 6 0.97 26.9 6 1.08 28.6 6 1.12 26.8 6 1.33 28.0 6 1.14
(6 SEM) CAPTIN 25.1 6 0.97* 28.4 6 1.16 26.5 6 1.18 27.8 6 1.58 27.8 6 1.15 29.0 6 1.58
Total 25.0 6 0.53 26.0 6 0.58 26.7 6 0.61 26.7 6 0.69 27.2 6 0.72 27.2 6 0.77
Mean CATS 54.9 6 1.26 54.3 6 1.26 58.7 6 1.33 57.3 6 1.34 60.5 6 1.64 59.1 6 1.71
LVEDVI FAMIS 53.4 6 1.32 54.7 6 1.49 57.7 6 1.49 58.8 6 1.69 58.8 6 1.69 59.1 6 1.56
(6 SEM) CAPTIN 50.8 6 1.14* 54.9 6 1.46 53.7 6 1.53 54.9 6 1.96 55.2 6 1.45 56.8 6 2.04
Total 53.1 6 0.72 54.6 6 0.74 57.0 6 0.84 57.2 6 0.90 58.3 6 0.93 58.5 6 1.02
*p , 0.05 for placebo vs. ACE inhibitor.
ACE 5 angiotensin-converting enzyme; LVESVI 5 left ventricular end-systolic volume index; LVEDVI 5 left ventricular end-diastolic volume index; other abbreviations
as in Table 1.
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patients who did not receive thrombolytic therapy (13–16).
In the most frequently cited clinical echocardiographic study
showing a beneficial effect of ACE inhibition on LV
dilation, only 17% of the patients underwent percutaneous
transluminal coronary angioplasty or thrombolytic therapy
(4). With the increase in the number of patients receiving
thrombolytic therapy, however, the effect of ACE inhibition
on LV dilation seemed to decrease. The echocardiographic
substudy of the Survival And Ventricular Enlargement
study (SAVE) showed only 3% diastolic and 5% systolic
volume attenuation after one year of treatment in 512
patients, 45% of whom received thrombolytic therapy (17).
In the echocardiographic substudy of the Gruppo Italiano
per lo Studio della Sopravvivenza nell’Infarto miocardico-3
(GISSI-3), 74% of the patients received reperfusion therapy
(18). In this substudy, attenuation of LV dilation at six
months was ,1%. The survival benefit of the ACE inhib-
itor lisinopril could therefore not be explained by the small
effect on ventricular dilation (19). In the Healing and Early
Afterload Reducing Therapy (HEART) trial, reperfusion
therapy was either thrombolysis or percutaneous translumi-
nal coronary angioplasty (20). After two weeks, no signifi-
cant effect on echocardiographic end points of both low and
Figure 2. The effect of ACE inhibitor treatment within 6 to 9 h on LV dilation after MI in various subgroups. Data are presented as the mean value and
95% CI. BSA 5 body surface area; CPK 5 creatine phosphokinase; MAP 5 mean arterial pressure.
Figure 3. The effect of ACE inhibitor treatment within 6 to 9 h on LV
dilation for patients in whom reperfusion therapy failed (n 5 212) after
MI. Data are presented as the mean value 6 SEM.
Figure 4. The effect of successful reperfusion after thrombolysis on LV
dilation for the placebo group (n 5 421) after MI. Data are presented as
the mean value 6 SEM.
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high dose ramipril, as compared with placebo, was found.
Only four other randomized, double-blind, placebo-
controlled studies using ACE inhibition and at least one
echocardiographic assessment after MI have been pub-
lished, in which all patients received reperfusion therapy
(2,21–23). Two small, explorative studies with one to two
weeks of echocardiographic follow-up showed significant
attenuation of LV dilation by ACE inhibitor as compared
with placebo (21,22). In contrast, in two larger studies
including ;500 patients, LV volumes were substantially
unchanged (2,24).
Patient selection. The second possible reason for our
finding of no significant attenuation of LV dilation may be
that patients included in this meta-analysis were not se-
lected on the basis of ventricular dysfunction. Most studies
investigated the effect of ACE inhibition on LV dilation in
patients with a depressed ejection fraction (,40% to 45%)
(25). These studies all showed a positive effect of ACE
inhibition on LV dilation. In the present study, only 13% of
the patients had an ejection fraction ,40%, probably caused
by the widespread use of thrombolysis, beta-blockers and
aspirin, which considerably increases the proportion of
patients with small, aborted MIs and normal LV function.
The effects of ACE inhibitors in patients with normal LV
function have not been extensively studied. Very recently,
however, the Heart Outcomes Prevention Evaluation
(HOPE) study clearly demonstrated reductions in mortality
and morbidity by treatment with an ACE inhibitor in
patients at high risk for cardiovascular events, but without
LV dysfunction or heart failure (26). Therefore, mecha-
nisms other than attenuation of LV dilation may be more
important in explaining the beneficial effect of ACE inhib-
itors in patients with normal LV function. These mecha-
nisms may include direct vasodilatory effects, antiprolifera-
tive effects on smooth muscle cells, protection from plaque
rupture, improved vascular endothelial function and en-
hanced fibrinolysis (27).
Timing of ACE inhibition. The third possible reason for
our finding of no significant attenuation of LV dilation may
be the very early start of ACE inhibitor treatment (i.e.,
within 6 to 9 h) after MI. A possible disadvantage of early
ACE inhibition after MI is early hypotension, which may
have been an important reason for the absence of survival
benefit in COoperative New Scandinavian ENalapril
SUrvival Study II (CONSENSUS-II) (28). Only few stud-
ies investigated the effect of very early treatment of ACE
inhibition on LV dilation. An experimental study in rats
showed a favorable effect on LV dilation with delayed
treatment rather than immediate ACE inhibitor treatment
(29). A small, explorative clinical study showed significant
attenuation of LV dilation, after one week of echocardio-
graphic follow-up, in which ACE inhibitor treatment was
given within 6 h after MI (21). The present meta-analysis,
however, could not confirm this finding. Whether the ACE
inhibitors were started too early after the onset of MI could
not be answered in this study. Subgroup analysis, however,
showed no significant effect on LV dilation, either in
patients treated with ACE inhibition within 3 h or patients
treated .3 h after MI (Fig. 2).
Study limitations. It must be underlined that a potential
limitation of this study is that it is a meta-analysis, which
may result in biased conclusions. To avoid this bias, we
systematically included the data of randomized, double-
blind, placebo-controlled studies (published and unpub-
lished data) that administered ACE inhibitors within 6 to
9 h after MI in patients receiving thrombolysis. Further-
more, these studies were the only confirmative studies ever
performed in this setting, with the primary end point being
evaluation of the effect of ACE inhibition on LV dilation.
Finally, the patient selection criteria and echocardiographic
methods were comparable, mainly because the studies were
conducted almost simultaneously, and the principal inves-
tigators communicated during the design and conduct of
each of the studies. Another important limitation of the
present study is that we assessed reperfusion by using
clinical variables instead of performing coronary angiogra-
phy. Also, a small proportion of patients crossed over from
the placebo group to the ACE inhibitor group, and it
cannot be ruled out that this may have diluted a possible
drug effect.
Conclusions. Attenuation of LV dilation by treatment
with an ACE inhibitor has mainly been investigated late
after MI in small, selected patient groups without the
widespread use of thrombolytic therapy. In this meta-
analysis involving 845 patients receiving thrombolysis, we
could not demonstrate attenuation of LV dilation by treat-
ment with an ACE inhibitor within 6 to 9 h after the
patients’ first (mainly) anterior MI. We speculate that very
early treatment with an ACE inhibitor has beneficial effects
on LV remodeling in patients in whom reperfusion failed.
Other mechanisms may be responsible for the beneficial
effects of ACE inhibitors in successfully reperfused patients
after MI.
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